Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dexcom (DXCM) Revenue (2016 - 2025)

Dexcom (DXCM) has disclosed Revenue for 16 consecutive years, with $1.3 billion as the latest value for Q4 2025.

  • Quarterly Revenue rose 13.12% to $1.3 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.7 billion through Dec 2025, up 15.6% year-over-year, with the annual reading at $4.7 billion for FY2025, 15.6% up from the prior year.
  • Revenue for Q4 2025 was $1.3 billion at Dexcom, up from $1.2 billion in the prior quarter.
  • The five-year high for Revenue was $1.3 billion in Q4 2025, with the low at $505.0 million in Q1 2021.
  • Average Revenue over 5 years is $883.8 million, with a median of $896.2 million recorded in 2023.
  • The sharpest move saw Revenue soared 31.72% in 2021, then rose 1.97% in 2024.
  • Over 5 years, Revenue stood at $698.2 million in 2021, then increased by 16.76% to $815.2 million in 2022, then grew by 26.9% to $1.0 billion in 2023, then increased by 7.64% to $1.1 billion in 2024, then increased by 13.12% to $1.3 billion in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $1.3 billion, $1.2 billion, and $1.2 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.